Sherlock at Apex of CRISPR-based Diagnostics after USPTO Grants Earliest Priority Patent
Watertown, Mass., Feb. 21, 2023
Sherlock Biosciences, a company engineering biology to bring next-generation lab-quality diagnostic testing to the point of need, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent for the diagnostic use of the Cas12 enzyme, establishing Sherlock as the leader in CRISPR-based diagnostics with freedom to operate in the U.S. Sherlock has exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech, plus additional intellectual property (IP) for Cas12 and Cas13 from the Broad Institute, giving the company the preeminent IP position in the space.
Read the PR here
Arsenal Biosciences, Inc.
M.D. Anderson Cancer Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University